C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy
Pharmaceutical Technology
NOVEMBER 28, 2022
According to the deal, C4XD is entitled to get up to $16m in pre-clinical milestone payments before the commencement of the first clinical trial. . A key natural regulator, NRF2 controls antioxidant genes’ expression. It is crucial in cellular defence against external insults and inflammatory response regulation. .
Let's personalize your content